{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:27:07Z","timestamp":1792682827503,"version":"4.5.0"},"reference-count":145,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T00:00:00Z","timestamp":1605744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000196","name":"Canada Foundation for Innovation","doi-asserted-by":"publisher","award":["35636"],"award-info":[{"award-number":["35636"]}],"id":[{"id":"10.13039\/501100000196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002300","name":"Rivkin Center for Ovarian Cancer","doi-asserted-by":"publisher","award":["567618"],"award-info":[{"award-number":["567618"]}],"id":[{"id":"10.13039\/100002300","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Traditional cancer treatments may lose efficacy following the emergence of novel mutations or the development of chemoradiotherapy resistance. Late diagnosis, high-cost of treatment, and the requirement of highly efficient infrastructure to dispense cancer therapies hinder the availability of adequate treatment in low-income and resource-limited settings. Repositioning approved drugs as cancer therapeutics may reduce the cost and timeline for novel drug development and expedite the availability of newer, efficacious options for patients in need. Nelfinavir is a human immunodeficiency virus (HIV) protease inhibitor that has been approved and is extensively used as an anti-infective agent to treat acquired immunodeficiency syndrome (AIDS). Yet nelfinavir has also shown anti-cancer effects in in vitro and in vivo studies. The anti-cancer mechanism of nelfinavir includes modulation of different cellular conditions, such as unfolded protein response, cell cycle, apoptosis, autophagy, the proteasome pathway, oxidative stress, the tumor microenvironment, and multidrug efflux pumps. Multiple clinical trials indicated tolerable and reversible toxicities during nelfinavir treatment in cancer patients, either as a monotherapy or in combination with chemo- or radiotherapy. Since orally available nelfinavir has been a safe drug of choice for both adult and pediatric HIV-infected patients for over two decades, exploiting its anti-cancer off-target effects will enable fast-tracking this newer option into the existing repertoire of cancer chemotherapeutics.<\/jats:p>","DOI":"10.3390\/cancers12113437","type":"journal-article","created":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T10:46:26Z","timestamp":1605782786000},"page":"3437","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["The Anti-Cancer Properties of the HIV Protease Inhibitor Nelfinavir"],"prefix":"10.3390","volume":"12","author":[{"given":"Mahbuba R.","family":"Subeha","sequence":"first","affiliation":[{"name":"Experimental Pathology Unit, Department of Pathology, McGill University, Montreal, QC H3A 2B4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1070-3538","authenticated-orcid":false,"given":"Carlos M.","family":"Telleria","sequence":"additional","affiliation":[{"name":"Experimental Pathology Unit, Department of Pathology, McGill University, Montreal, QC H3A 2B4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,11,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1056\/NEJM199804303381808","article-title":"HIV-protease inhibitors","volume":"338","author":"Flexner","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1089\/aid.1992.8.153","article-title":"The HIV-1 protease as a therapeutic target for AIDS","volume":"8","author":"Debouck","year":"1992","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"ref_3","first-page":"95","article-title":"HIV protease inhibitors: A review of molecular selectivity and toxicity","volume":"7","author":"Lv","year":"2015","journal-title":"HIV AIDS (Auckl)"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1002\/ijc.30529","article-title":"HIV-protease inhibitors for the treatment of cancer: Repositioning HIV protease inhibitors while developing more potent NO-hybridized derivatives?","volume":"140","author":"Fagone","year":"2017","journal-title":"Int. J. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/jama.280.1.78","article-title":"Antiretroviral therapy for HIV infection in 1998: Updated recommendations of the International AIDS Society-USA Panel","volume":"280","author":"Carpenter","year":"1998","journal-title":"JAMA"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1128\/AAC.45.4.1086-1093.2001","article-title":"Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: Structural identification, levels in plasma, and antiviral activities","volume":"45","author":"Zhang","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1097\/00002030-199906180-00026","article-title":"Complete regression of AIDS-related Kaposi\u2019s sarcoma in a child treated with highly active antiretroviral therapy","volume":"13","author":"Niehues","year":"1999","journal-title":"AIDS"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"F45","DOI":"10.1097\/00002030-199807000-00002","article-title":"Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi\u2019s sarcoma","volume":"12","author":"Lebbe","year":"1998","journal-title":"AIDS"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S0190-9622(98)70124-0","article-title":"Regression of Kaposi\u2019s sarcoma during therapy with HIV-1 protease inhibitors: A prospective pilot study","volume":"38","author":"Krischer","year":"1998","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nm0302-225","article-title":"HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma","volume":"8","author":"Sgadari","year":"2002","journal-title":"Nat. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S1470-2045(03)01192-6","article-title":"Use of HIV protease inhibitors to block Kaposi\u2019s sarcoma and tumour growth","volume":"4","author":"Sgadari","year":"2003","journal-title":"Lancet Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"35734","DOI":"10.1074\/jbc.274.50.35734","article-title":"How an inhibitor of the HIV-I protease modulates proteasome activity","volume":"274","author":"Schmidtke","year":"1999","journal-title":"J. Biol. Chem."},{"key":"ref_13","first-page":"325","article-title":"Nelfinavir mesylate: A protease inhibitor","volume":"33","author":"Pai","year":"1999","journal-title":"Ann. Pharm."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.12688\/f1000research.5827.2","article-title":"Nelfinavir and other protease inhibitors in cancer: Mechanisms involved in anticancer activity","volume":"4","author":"Koltai","year":"2015","journal-title":"F1000Res"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/CCO.0b013e328363dfee","article-title":"Insights into the broad cellular effects of nelfinavir and the HIV protease inhibitors supporting their role in cancer treatment and prevention","volume":"25","author":"Gantt","year":"2013","journal-title":"Curr. Opin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"233","DOI":"10.4161\/cbt.8.3.7789","article-title":"Nelfinavir: A magic bullet to annihilate cancer cells?","volume":"8","author":"Wu","year":"2009","journal-title":"Cancer Biol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Xie, L., Evangelidis, T., Xie, L., and Bourne, P.E. (2011). Drug Discovery Using Chemical Systems Biology: Weak Inhibition of Multiple Kinases May Contribute to the Anti-Cancer Effect of Nelfinavir. PLoS Comput. Biol., 7.","DOI":"10.1371\/journal.pcbi.1002037"},{"key":"ref_18","first-page":"6055","article-title":"Could the FDA-approved anti-HIV PR inhibitors be promising anticancer agents? An answer from enhanced docking approach and molecular dynamics analyses","volume":"9","author":"Arodola","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5183","DOI":"10.1158\/1078-0432.CCR-07-0161","article-title":"Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo","volume":"13","author":"Gills","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1182\/blood-2018-05-851170","article-title":"Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor-refractory multiple myeloma","volume":"132","author":"Driessen","year":"2018","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"226","DOI":"10.4161\/cbt.8.3.7339","article-title":"Nelfinavir induces the unfolded protein response in ovarian cancer cells, resulting in ER vacuolization, cell cycle retardation and apoptosis","volume":"8","author":"Bruning","year":"2009","journal-title":"Cancer Biol. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1476-4598-9-19","article-title":"The mitochondria-independent cytotoxic effect of nelfinavir on leukemia cells can be enhanced by sorafenib-mediated mcl-1 downregulation and mitochondrial membrane destabilization","volume":"9","author":"Bruning","year":"2010","journal-title":"Mol. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2174\/156800911796798913","article-title":"Bortezomib targets the caspase-like proteasome activity in cervical cancer cells, triggering apoptosis that can be enhanced by nelfinavir","volume":"11","author":"Bruning","year":"2011","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1097\/01.cad.0000224448.08706.76","article-title":"Nelfinavir induces liposarcoma apoptosis and cell cycle arrest by upregulating sterol regulatory element binding protein-1","volume":"17","author":"Chow","year":"2006","journal-title":"Anticancer Drugs"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1158\/0008-5472.CAN-06-3377","article-title":"HIV protease inhibitor nelfinavir inhibits growth of human melanoma cells by induction of cell cycle arrest","volume":"67","author":"Jiang","year":"2007","journal-title":"Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1530\/ERC-16-0568","article-title":"Nelfinavir inhibits proliferation and induces DNA damage in thyroid cancer cells","volume":"24","author":"Jensen","year":"2017","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3727\/096504017X14957929842972","article-title":"Nelfinavir and Ritonavir Kill Bladder Cancer Cells Synergistically by Inducing Endoplasmic Reticulum Stress","volume":"26","author":"Sato","year":"2018","journal-title":"Oncol. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.21873\/anticanres.12754","article-title":"Nelfinavir Induces Endoplasmic Reticulum Stress and Sensitizes Renal Cancer Cells to TRAIL","volume":"38","author":"Okubo","year":"2018","journal-title":"Anticancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5615","DOI":"10.21873\/anticanres.12896","article-title":"Panobinostat and Nelfinavir Inhibit Renal Cancer Growth by Inducing Endoplasmic Reticulum Stress","volume":"38","author":"Okubo","year":"2018","journal-title":"Anticancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Soprano, M., Sorriento, D., Rusciano, M.R., Maione, A.S., Limite, G., Forestieri, P., D\u2019Angelo, D., D\u2019Alessio, M., Campiglia, P., and Formisano, P. (2016). Oxidative Stress Mediates the Antiproliferative Effects of Nelfinavir in Breast Cancer Cells. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0155970"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1179\/1973947812Y.0000000011","article-title":"Antitumour effects of a protease inhibitor, nelfinavir, in hepatocellular carcinoma cancer cells","volume":"24","author":"Sun","year":"2012","journal-title":"J. Chemother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s13046-018-0904-2","article-title":"Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells","volume":"37","author":"Veschi","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.canlet.2015.04.027","article-title":"Nelfinavir, an HIV protease inhibitor, induces apoptosis and cell cycle arrest in human cervical cancer cells via the ROS-dependent mitochondrial pathway","volume":"364","author":"Xiang","year":"2015","journal-title":"Cancer Lett."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"43373","DOI":"10.1038\/srep43373","article-title":"Combining metformin and nelfinavir exhibits synergistic effects against the growth of human cervical cancer cells and xenograft in nude mice","volume":"7","author":"Xia","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s10637-009-9281-1","article-title":"Nelfinavir induces mitochondria protection by ERK1\/2-mediated mcl-1 stabilization that can be overcome by sorafenib","volume":"28","author":"Bruning","year":"2010","journal-title":"Investig. New Drugs"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4727","DOI":"10.1242\/jcs.00210","article-title":"Apoptosis-inducing factor (AIF): Key to the conserved caspase-independent pathways of cell death?","volume":"115","author":"Cande","year":"2002","journal-title":"J. Cell Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.3324\/haematol.2011.049981","article-title":"The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo","volume":"97","author":"Bono","year":"2012","journal-title":"Haematologica"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"E734","DOI":"10.1210\/jc.2013-3369","article-title":"The HIV protease inhibitor nelfinavir down-regulates RET signaling and induces apoptosis in medullary thyroid cancer cells","volume":"99","author":"Kushchayeva","year":"2014","journal-title":"J. Clinl. Endocrinol. Metabol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"R45","DOI":"10.1186\/bcr2602","article-title":"Tamoxifen enhances the cytotoxic effects of nelfinavir in breast cancer cells","volume":"12","author":"Bruning","year":"2010","journal-title":"Breast Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.canlet.2009.03.007","article-title":"Enhanced killing of chemo-resistant breast cancer cells via controlled aggravation of ER stress","volume":"282","author":"Cho","year":"2009","journal-title":"Cancer Lett."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.canlet.2012.05.030","article-title":"Preferential killing of triple-negative breast cancer cells in vitro and in vivo when pharmacological aggravators of endoplasmic reticulum stress are combined with autophagy inhibitors","volume":"325","author":"Thomas","year":"2012","journal-title":"Cancer Lett."},{"key":"ref_42","first-page":"1837","article-title":"Nelfinavir is effective against human cervical cancer cells in vivo: A potential treatment modality in resource-limited settings","volume":"10","author":"Davis","year":"2016","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.molonc.2013.07.010","article-title":"Nelfinavir and bortezomib inhibit mTOR activity via ATF4-mediated sestrin-2 regulation","volume":"7","author":"Bruning","year":"2013","journal-title":"Mol. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.2147\/OTT.S136484","article-title":"The HIV protease inhibitor, nelfinavir, as a novel therapeutic approach for the treatment of refractory pediatric leukemia","volume":"10","author":"Riemer","year":"2017","journal-title":"Onco. Targets Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1159\/000495650","article-title":"Targeting P-Glycoprotein: Nelfinavir Reverses Adriamycin Resistance in K562\/ADR Cells","volume":"51","author":"Liu","year":"2018","journal-title":"Cell Physiol. Biochem."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Mathur, A., Abd Elmageed, Z.Y., Liu, X., Kostochka, M.L., Zhang, H., Abdel-Mageed, A.B., and Mondal, D. (2014). Subverting ER-stress towards apoptosis by nelfinavir and curcumin coexposure augments docetaxel efficacy in castration resistant prostate cancer cells. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0103109"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1038\/sj.bjc.6603435","article-title":"NFV, an HIV-1 protease inhibitor, induces growth arrest, reduced Akt signalling, apoptosis and docetaxel sensitisation in NSCLC cell lines","volume":"95","author":"Yang","year":"2006","journal-title":"Br. J. Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1349-7006.2005.00063.x","article-title":"HIV-1 protease inhibitor induces growth arrest and apoptosis of human prostate cancer LNCaP cells in vitro and in vivo in conjunction with blockade of androgen receptor STAT3 and AKT signaling","volume":"96","author":"Yang","year":"2005","journal-title":"Cancer Sci."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"34988","DOI":"10.18632\/oncotarget.9222","article-title":"Next-generation proteasome inhibitor oprozomib synergizes with modulators of the unfolded protein response to suppress hepatocellular carcinoma","volume":"7","author":"Vandewynckel","year":"2016","journal-title":"Oncotarget"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"E9","DOI":"10.3171\/FOC-07\/10\/E9","article-title":"Nelfinavir potentiation of imatinib cytotoxicity in meningioma cells via survivin inhibition","volume":"23","author":"Gupta","year":"2007","journal-title":"Neurosurg. Focus"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/01926230701320337","article-title":"Apoptosis: A review of programmed cell death","volume":"35","author":"Elmore","year":"2007","journal-title":"Toxicol. Pathol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"29408","DOI":"10.1074\/jbc.M110.197665","article-title":"Modulation of CCAAT\/enhancer binding protein homologous protein (CHOP)-dependent DR5 expression by nelfinavir sensitizes glioblastoma multiforme cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)","volume":"286","author":"Tian","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.bbrc.2008.10.167","article-title":"Nelfinavir induces TRAIL receptor upregulation in ovarian cancer cells","volume":"377","author":"Bruning","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1016\/j.bbamcr.2014.01.012","article-title":"Endoplasmic reticulum stress associated responses in cancer","volume":"1843","author":"Wang","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3389\/fonc.2017.00078","article-title":"Endoplasmic Reticulum Stress, Unfolded Protein Response, and Cancer Cell Fate","volume":"7","author":"Corazzari","year":"2017","journal-title":"Front Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e353","DOI":"10.1038\/cddis.2012.87","article-title":"Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells","volume":"3","author":"Kawabata","year":"2012","journal-title":"Cell Death Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"8161","DOI":"10.18632\/oncotarget.2415","article-title":"A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumors","volume":"5","author":"Blumenthal","year":"2014","journal-title":"Oncotarget"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"10920","DOI":"10.1158\/0008-5472.CAN-07-0796","article-title":"HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress","volume":"67","author":"Pyrko","year":"2007","journal-title":"Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/s41467-020-15067-5","article-title":"Pharmacological induction of selective endoplasmic reticulum retention as a strategy for cancer therapy","volume":"11","author":"Mahameed","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.biochi.2016.01.014","article-title":"Nelfinavir targets multiple drug resistance mechanisms to increase the efficacy of doxorubicin in MCF-7\/Dox breast cancer cells","volume":"124","author":"Chakravarty","year":"2016","journal-title":"Biochimie"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1158\/1078-0432.CCR-10-3216","article-title":"Nelfinavir induces liposarcoma apoptosis through inhibition of regulated intramembrane proteolysis of SREBP-1 and ATF6","volume":"17","author":"Guan","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1111\/j.1742-4658.2012.08619.x","article-title":"Nelfinavir inhibits regulated intramembrane proteolysis of sterol regulatory element binding protein-1 and activating transcription factor 6 in castration-resistant prostate cancer","volume":"279","author":"Guan","year":"2012","journal-title":"FEBS J."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1006\/bbrc.2001.5375","article-title":"Sterol regulatory element-binding proteins induce an entire pathway of cholesterol synthesis","volume":"286","author":"Sakakura","year":"2001","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0092-8674(00)80675-3","article-title":"Regulated intramembrane proteolysis: A control mechanism conserved from bacteria to humans","volume":"100","author":"Brown","year":"2000","journal-title":"Cell"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"9698","DOI":"10.1038\/srep09698","article-title":"Nelfinavir and nelfinavir analogs block site-2 protease cleavage to inhibit castration-resistant prostate cancer","volume":"5","author":"Guan","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/15384101.2016.1254974","article-title":"Translating the anticancer properties of eEF2K","volume":"16","author":"Martinon","year":"2017","journal-title":"Cell Cycle."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.15252\/embr.201642194","article-title":"Pharmacological eEF2K activation promotes cell death and inhibits cancer progression","volume":"17","author":"Demaria","year":"2016","journal-title":"EMBO Rep."},{"key":"ref_68","first-page":"E117","article-title":"An inhibitor of HIV-1 protease modulates constitutive eIF2\u03b1 dephosphorylation to trigger a specific integrated stress response","volume":"113","author":"Bujisic","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.molonc.2014.11.005","article-title":"Endoplasmic reticulum stress and cell death in mTORC1-overactive cells is induced by nelfinavir and enhanced by chloroquine","volume":"9","author":"Johnson","year":"2015","journal-title":"Mol. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"5913","DOI":"10.1038\/s41388-018-0381-2","article-title":"Loss of tuberous sclerosis complex 2 sensitizes tumors to nelfinavir-bortezomib therapy to intensify endoplasmic reticulum stress-induced cell death","volume":"37","author":"Johnson","year":"2018","journal-title":"Oncogene"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"48711","DOI":"10.18632\/oncotarget.16232","article-title":"Targeting protein homeostasis with nelfinavir\/salinomycin dual therapy effectively induces death of mTORC1 hyperactive cells","volume":"8","author":"Dunlop","year":"2017","journal-title":"Oncotarget"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"McCann, H.D., Johnson, C.E., Errington, R.J., Davies, D.M., Dunlop, E.A., and Tee, A.R. (2018). Energy Stress-Mediated Cytotoxicity in Tuberous Sclerosis Complex 2-Deficient Cells with Nelfinavir and Mefloquine Treatment. Cancers, 10.","DOI":"10.3390\/cancers10100375"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1038\/bcj.2013.2","article-title":"Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance","volume":"3","author":"Kraus","year":"2013","journal-title":"Blood Cancer J."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.leukres.2013.12.017","article-title":"Ritonavir, nelfinavir, saquinavir and lopinavir induce proteotoxic stress in acute myeloid leukemia cells and sensitize them for proteasome inhibitor treatment at low micromolar drug concentrations","volume":"38","author":"Kraus","year":"2014","journal-title":"Leuk Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3324\/haematol.2015.135780","article-title":"Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: A phase I trial (SAKK 65\/08)","volume":"101","author":"Driessen","year":"2016","journal-title":"Haematologica"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41408-019-0228-2","article-title":"Nelfinavir and lenalidomide\/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I\/II Trial (SAKK 39\/10)","volume":"9","author":"Hitz","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.3109\/10428194.2013.781168","article-title":"Identification of endoplasmic reticulum stress-inducing agents by antagonizing autophagy: A new potential strategy for identification of anti-cancer therapeutics in B-cell malignancies","volume":"54","author":"Mahoney","year":"2013","journal-title":"Leuk Lymphoma."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Yoshii, S.R., and Mizushima, N. (2017). Monitoring and Measuring Autophagy. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18091865"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"542","DOI":"10.4161\/auto.4600","article-title":"How to interpret LC3 immunoblotting","volume":"3","author":"Mizushima","year":"2007","journal-title":"Autophagy"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4161\/auto.5224","article-title":"Nelfinavir, a new anti-cancer drug with pleiotropic effects and many paths to autophagy","volume":"4","author":"Gills","year":"2008","journal-title":"Autophagy"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1007\/s00280-013-2156-3","article-title":"Preventing the autophagic survival response by inhibition of calpain enhances the cytotoxic activity of bortezomib in vitro and in vivo","volume":"71","author":"Escalante","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1083\/jcb.200601024","article-title":"Calpain is required for macroautophagy in mammalian cells","volume":"175","author":"Demarchi","year":"2006","journal-title":"J. Cell Biol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"33713","DOI":"10.1074\/jbc.R109.018481","article-title":"The 26 S proteasome: From basic mechanisms to drug targeting","volume":"284","author":"Navon","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): A randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.str.2005.11.019","article-title":"Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome","volume":"14","author":"Groll","year":"2006","journal-title":"Structure"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.1158\/0008-5472.CAN-06-4086","article-title":"Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome","volume":"67","author":"Demo","year":"2007","journal-title":"Cancer Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/leu.2017.212","article-title":"Carfilzomib resistance due to ABCB1\/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma","volume":"32","author":"Besse","year":"2018","journal-title":"Leukemia"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1093\/jnci\/djs396","article-title":"Selective inhibition of HER2-positive breast cancer cells by the HIV protease inhibitor nelfinavir","volume":"104","author":"Shim","year":"2012","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1593\/neo.07124","article-title":"The HIV protease inhibitor nelfinavir downregulates Akt phosphorylation by inhibiting proteasomal activity and inducing the unfolded protein response","volume":"9","author":"Gupta","year":"2007","journal-title":"Neoplasia"},{"key":"ref_90","first-page":"5230","article-title":"The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells","volume":"62","author":"Pajonk","year":"2002","journal-title":"Cancer Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1177\/135965350501000203","article-title":"The HIV protease inhibitors nelfinavir and saquinavir, but not a variety of HIV reverse transcriptase inhibitors, adversely affect human proteasome function","volume":"10","author":"Piccinini","year":"2005","journal-title":"Antivir. Ther."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Fassmannov\u00e1, D., Sedl\u00e1k, F., Sedl\u00e1\u010dek, J., \u0160pi\u010dka, I., and Grantz \u0160a\u0161kov\u00e1, K. (2020). Nelfinavir Inhibits the TCF11\/Nrf1-Mediated proteasome recovery pathway in multiple myeloma. Cancers, 12.","DOI":"10.3390\/cancers12051065"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1210\/jc.2009-2315","article-title":"RET is a heat shock protein 90 (HSP90) client protein and is knocked down upon HSP90 pharmacological block","volume":"95","author":"Alfano","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"6056","DOI":"10.1038\/sj.onc.1207810","article-title":"Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors","volume":"23","author":"Carlomagno","year":"2004","journal-title":"Oncogene"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1158\/1078-0432.CCR-11-1407","article-title":"Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma","volume":"18","author":"Petrich","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"8256","DOI":"10.1158\/0008-5472.CAN-05-1220","article-title":"HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo","volume":"65","author":"Gupta","year":"2005","journal-title":"Cancer Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"145","DOI":"10.4103\/0971-5916.180201","article-title":"Targeting the AKT pathway: Repositioning HIV protease inhibitors as radiosensitizers","volume":"143","author":"Goda","year":"2016","journal-title":"Indian J. Med. Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"636","DOI":"10.4161\/cbt.7.5.6087","article-title":"Progress towards the use of HIV protease inhibitors in cancer therapy","volume":"7","author":"Bernhard","year":"2008","journal-title":"Cancer Biol. Ther."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.ijrobp.2009.03.004","article-title":"Radiation response in two HPV-infected head-and-neck cancer cell lines in comparison to a non-HPV-infected cell line and relationship to signaling through AKT","volume":"74","author":"Gupta","year":"2009","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"4467","DOI":"10.1158\/0008-5472.CAN-06-3398","article-title":"Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir","volume":"67","author":"Jiang","year":"2007","journal-title":"Cancer Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1158\/1078-0432.CCR-09-1324","article-title":"Radiosensitization of epidermal growth factor receptor\/HER2-positive pancreatic cancer is mediated by inhibition of Akt independent of ras mutational status","volume":"16","author":"Kimple","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"4886","DOI":"10.1158\/0008-5472.CAN-06-3684","article-title":"HIV protease inhibitors enhance the efficacy of irradiation","volume":"67","author":"Cuneo","year":"2007","journal-title":"Cancer Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"9252","DOI":"10.1158\/0008-5472.CAN-06-1239","article-title":"Nelfinavir down-regulates hypoxia-inducible factor 1alpha and VEGF expression and increases tumor oxygenation: Implications for radiotherapy","volume":"66","author":"Pore","year":"2006","journal-title":"Cancer Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1593\/neo.06535","article-title":"HIV protease inhibitors decrease VEGF\/HIF-1alpha expression and angiogenesis in glioblastoma cells","volume":"8","author":"Pore","year":"2006","journal-title":"Neoplasia"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"657","DOI":"10.4161\/cbt.12.7.17172","article-title":"Nelfinavir induces radiation sensitization in pituitary adenoma cells","volume":"12","author":"Zeng","year":"2011","journal-title":"Cancer Biol. Ther."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"628","DOI":"10.4161\/cbt.7.5.5728","article-title":"Validation and toxicity of PI3K\/Akt pathway inhibition by HIV protease inhibitors in humans","volume":"7","author":"Plastaras","year":"2008","journal-title":"Cancer Biol. Ther."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1200\/JCO.2007.15.2355","article-title":"Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer","volume":"26","author":"Brunner","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.4161\/cbt.8.20.9596","article-title":"Signaling pathways in adenoid cystic cancers: Implications for treatment","volume":"8","author":"Gupta","year":"2009","journal-title":"Cancer Biol. Ther."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/hed.23664","article-title":"Efficacy of nelfinavir as monotherapy in refractory adenoid cystic carcinoma: Results of a phase II clinical trial","volume":"37","author":"Hoover","year":"2015","journal-title":"Head Neck"},{"key":"ref_110","first-page":"7","article-title":"The HIV protease and PI3K\/Akt inhibitor nelfinavir does not improve the curative effect of fractionated irradiation in PC-3 prostate cancer in vitro and in vivo","volume":"2","author":"Liebscher","year":"2017","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1586\/ecp.11.37","article-title":"Targeting the off-targets: A computational bioinformatics approach to understanding the polypharmacology of nelfinavir","volume":"4","author":"Bruning","year":"2011","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/1535-7163.473.3.4","article-title":"HIV-1 protease inhibitor induces growth arrest and apoptosis of human multiple myeloma cells via inactivation of signal transducer and activator of transcription 3 and extracellular signal-regulated kinase 1\/2","volume":"3","author":"Ikezoe","year":"2004","journal-title":"Mol. Cancer Ther."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ccell.2016.02.003","article-title":"Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy","volume":"29","author":"Smith","year":"2016","journal-title":"Cancer Cell"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"26729","DOI":"10.1074\/jbc.C500186200","article-title":"Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: A novel basis for antileukemia activity of histone deacetylase inhibitors","volume":"280","author":"Bali","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"294303","DOI":"10.1155\/2015\/294303","article-title":"Increased Oxidative Stress as a Selective Anticancer Therapy","volume":"2015","author":"Liu","year":"2015","journal-title":"Oxid. Med. Cell Longev."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"R183","DOI":"10.1530\/ERC-13-0473","article-title":"Repositioning therapy for thyroid cancer: New insights on established medications","volume":"21","author":"Kushchayeva","year":"2014","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejphar.2019.01.045","article-title":"Metformin combined with nelfinavir induces SIRT3\/mROS-dependent autophagy in human cervical cancer cells and xenograft in nude mice","volume":"848","author":"Xia","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"e1047","DOI":"10.1038\/cddis.2014.14","article-title":"Sirtuin-3 (SIRT3), a therapeutic target with oncogenic and tumor-suppressive function in cancer","volume":"5","author":"Chen","year":"2014","journal-title":"Cell Death Dis."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"442","DOI":"10.2174\/156652409788167087","article-title":"Hypoxia and radiation therapy: Past history, ongoing research, and future promise","volume":"9","author":"Rockwell","year":"2009","journal-title":"Curr. Mol. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1158\/1078-0432.CCR-11-1413","article-title":"Modulation of the tumor microvasculature by phosphoinositide-3 kinase inhibition increases doxorubicin delivery in vivo","volume":"18","author":"Qayum","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1124\/jpet.104.077263","article-title":"Protease inhibitor treatments reveal specific involvement of matrix metalloproteinase-9 in human adipocyte differentiation","volume":"312","author":"Bourlier","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.arcmed.2012.04.005","article-title":"Matrix metalloproteinase-2 and -9 in glioblastoma: A trio of old drugs-captopril, disulfiram and nelfinavir-are inhibitors with potential as adjunctive treatments in glioblastoma","volume":"43","author":"Kast","year":"2012","journal-title":"Arch. Med. Res."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.radonc.2016.03.024","article-title":"The radiosensitizing effects of Nelfinavir on pancreatic cancer with and without pancreatic stellate cells","volume":"119","author":"Bittner","year":"2016","journal-title":"Radiother. Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"e706","DOI":"10.1038\/cddis.2013.206","article-title":"Targeting cancer stem cells expressing an embryonic signature with anti-proteases to decrease their tumor potential","volume":"4","author":"Darini","year":"2013","journal-title":"Cell Death. Dis."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Giardino Torchia, M.L., Ciaglia, E., Masci, A.M., Vitiello, L., Fogli, M., la Sala, A., Mavilio, D., and Racioppi, L. (2010). Dendritic cells\/natural killer cross-talk: A novel target for human immunodeficiency virus type-1 protease inhibitors. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0011052"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/nrm2646","article-title":"ABC transporters: The power to change","volume":"10","author":"Rees","year":"2009","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"20310","DOI":"10.1074\/jbc.M500737200","article-title":"Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2","volume":"280","author":"Misra","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.21873\/anticanres.13524","article-title":"Co-treatment With HIV Protease Inhibitor Nelfinavir Greatly Increases Late-phase Apoptosis of Drug-resistant KBV20C Cancer Cells Independently of P-Glycoprotein Inhibition","volume":"39","author":"Kim","year":"2019","journal-title":"Anticancer Res."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/bjc.2011.275","article-title":"Exposure to HIV-protease inhibitors selects for increased expression of P-glycoprotein (ABCB1) in Kaposi\u2019s sarcoma cells","volume":"105","author":"Lucia","year":"2011","journal-title":"Br. J. Cancer"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1097\/00002030-200006160-00034","article-title":"Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture","volume":"14","author":"Perloff","year":"2000","journal-title":"AIDS"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1124\/jpet.104.065342","article-title":"HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP\/ABCG2)","volume":"310","author":"Gupta","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1124\/mol.113.086967","article-title":"Human immunodeficiency virus protease inhibitors interact with ATP binding cassette transporter 4\/multidrug resistance protein 4: A basis for unanticipated enhanced cytotoxicity","volume":"84","author":"Fukuda","year":"2013","journal-title":"Mol. Pharmacol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/JTO.0b013e3182435aa6","article-title":"A phase I trial of the HIV protease inhibitor nelfinavir with concurrent chemoradiotherapy for unresectable stage IIIA\/IIIB non-small cell lung cancer: A report of toxicities and clinical response","volume":"7","author":"Rengan","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1001\/jamaoncol.2019.2095","article-title":"Clinical Outcomes of the HIV Protease Inhibitor Nelfinavir With Concurrent Chemoradiotherapy for Unresectable Stage IIIA\/IIIB Non-Small Cell Lung Cancer: A Phase 1\/2 Trial","volume":"5","author":"Rengan","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.radonc.2016.03.021","article-title":"ARCII: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer","volume":"119","author":"Wilson","year":"2016","journal-title":"Radiother. Oncol."},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Strauss, V.Y., Shaw, R., Virdee, P.S., Hurt, C.N., Ward, E., Tranter, B., Patel, N., Bridgewater, J., Parsons, P., and Radhakrishna, G. (2019). Study protocol: A multi-centre randomised study of induction chemotherapy followed by capecitabine +\/\u2212 nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2). BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5307-z"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.radonc.2018.11.002","article-title":"Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma","volume":"132","author":"Lin","year":"2019","journal-title":"Radiother. Oncol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/COC.0000000000000599","article-title":"Phase I\/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic Adenocarcinoma","volume":"42","author":"Lin","year":"2019","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s00280-012-1961-4","article-title":"Phase I study of nelfinavir in liposarcoma","volume":"70","author":"Pan","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ccr.2013.08.009","article-title":"Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma","volume":"24","author":"Erdmann","year":"2013","journal-title":"Cancer Cell"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1158\/1078-0432.CCR-15-1489","article-title":"Clinical Trial of Oral Nelfinavir before and during Radiation Therapy for Advanced Rectal Cancer","volume":"22","author":"Hill","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.radonc.2013.03.023","article-title":"Phase I trial of the combination of the Akt inhibitor nelfinavir and chemoradiation for locally advanced rectal cancer","volume":"107","author":"Buijsen","year":"2013","journal-title":"Radiother. Oncol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1097\/COH.0b013e328313915d","article-title":"Repositioning HIV protease inhibitors as cancer therapeutics","volume":"3","author":"Bernstein","year":"2008","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s11060-013-1303-3","article-title":"A phase I study of nelfinavir concurrent with temozolomide and radiotherapy in patients with glioblastoma multiforme","volume":"116","author":"Fang","year":"2014","journal-title":"J. Neurooncol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/bcp.12620","article-title":"Impact of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir in patients with pancreatic cancer","volume":"80","author":"Kattel","year":"2015","journal-title":"Br. J. Clin. Pharmacol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/11\/3437\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:34:33Z","timestamp":1760178873000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/11\/3437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,19]]},"references-count":145,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11]]}},"alternative-id":["cancers12113437"],"URL":"https:\/\/doi.org\/10.3390\/cancers12113437","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,19]]}}}